Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India
Shots:
- Glenmark has received the DCGI’s approval to initiate P-III FAITH study assessing Favipiravir + Umifenovir + SOC and Favipiravir + SOC in 158 hospitalized patients with moderate COVID-19. On day 1, patients will receive Faviprivir (1800mg, bid) and Umifenovir (800mg, bid), followed by 800mg of each for the remaining course of the treatment
- Treatment duration of the study is 14days and patients will be discharged after clinical cure & two consecutive negative tests for COVID-19 based on RT-PCR. The two antivirals with different MOA complement and enhance efficacy against COVID-19
- Additionally, Glenmark is evaluating Favipiravir in P-III clinical study as monothx. with 150 patients with COVID-19 with its anticipated results in Jul/ Aug’2020. Glenmark is the first company to receive DCGI’s approval to conduct clinical trials of Favipiravir against COVID-19 in India
Click here to read full press release/ article | Ref: Glenmark | Image: Glenmark